PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics Limited has announced the initiation of clinical trials in Australia for its innovative drug, PYC-001, targeting Autosomal Dominant Optic Atrophy (ADOA), a rare blinding eye disease with no current treatments. The first-in-human studies follow promising safety and efficacy profiles from previous programs, with the company aiming to collect initial data by 2025 to support further development. PYC-001, which has received Orphan Drug Designation from the FDA, leverages the company’s proprietary technology to potentially modify the disease by restoring normal gene expression.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
